As the healthcare landscape undergoes a seismic shift toward consolidation, the financial burden on American families continues to reach unprecedented levels. Faisal Zain, a seasoned expert in medical technology and healthcare manufacturing, has spent years observing how innovation in the diagnostic and surgical sectors intersects with the complex economics of hospital management. With a unique perspective on how medical devices and advanced treatments are priced and deployed, Zain offers a deep dive into the growing trend of hospital monopolies and their direct impact on the cost of care. In the following discussion, we explore the stark reality of price disparities across the United States, the role of federal and state oversight in curbing anti-competitive mergers, and the real-world consequences for patients who find themselves caught in a system where bargaining power often dictates the price of a life-improving surgery.
A routine knee replacement can cost $16,000 in one city but soar to $40,000 just an hour away. How do we explain such a massive disparity for the exact same medical procedure?
The staggering gap we see between $16,000 at Catawba Valley Medical Center and $40,000 at Mission Hospital in Asheville is not a result of superior technology or better outcomes, but rather a reflection of pure market power. When you have a region like Asheville where a merger between St. Joseph’s Hospital and Memorial Mission Medical Center created a dominant entity, that system gains the leverage to demand nearly double or triple the rates from insurers like Blue Cross Blue Shield. In my experience with medical device manufacturing, I see how technology is often used as a justification for these costs, but the reality is that hospitals with few competitors can simply charge more because there is nowhere else for the patient to go. This isn’t just happening in North Carolina; we see similar patterns at Holmes Regional Medical Center in Florida, which has charged Cigna double the rate of hospitals just two hours away. It is a classic example of how bargaining leverage, rather than clinical value, has become the primary driver of healthcare inflation in the United States.
With over 1,000 hospital mergers occurring between 2002 and 2020, how has this trend towards “mega-mergers” fundamentally altered the financial landscape for the average American family?
The wave of consolidation has created a “fiscally sustainable environment” for the hospitals, as the American Hospital Association claims, but it has been a financial catastrophe for the average family. We are seeing these massive interstate systems, like the one merging 28 hospitals across Connecticut and New York or the Sanford Health and Marshfield Clinic deal that created a 56-hospital system with $10 billion in revenue. These entities have so much gravity that they pull insurance premiums upward for everyone, not just the people who are sick. For instance, the total cost for an employer to provide a family health insurance plan has surged to over $27,000 in 2025, a significant jump from just $21,000 only six years ago. When a hospital like Mission Hospital in Asheville becomes the only option in town, local business owners like Katie Button of Cúrate restaurant are forced to pay these exorbitant premiums because any viable insurance plan must include the dominant local provider.
Until recently, hospital pricing was shrouded in mystery, but new transparency rules are changing the game. How has the 2021 federal disclosure rule impacted our understanding of hospital monopolies?
For decades, economists like Zack Cooper at Yale suspected that mergers were the main engine behind rising costs, but the data was effectively locked behind a curtain because hospitals do not advertise their prices and insurers kept their negotiated rates secret. Since the Centers for Medicare & Medicaid Services began requiring hospitals to disclose their prices in 2021, we finally have the “smoking gun” through data collected by firms like Serif Health. This transparency has revealed that the prices we pay are almost entirely uncorrelated to the value we receive; for example, a breast biopsy that costs $1,700 at Catawba Valley costs $7,500 at Mission Hospital under the same UnitedHealthcare plan. This data allows us to see that Mission Hospital’s prices are 334% of what Medicare pays, while the state benchmark sits much lower at 280%. Without these disclosure rules, the public and regulators would still be guessing about the true extent of the “monopoly tax” being levied on patients.
When we look at the human element, stories like Marcelle Crago’s show patients being quoted $9,000 for a meniscus surgery that costs a fraction of that elsewhere. What does this tell us about the “shopping around” philosophy often touted by hospital executives?
The idea that a patient can “shop around” while in pain or facing a medical crisis is often a hollow promise, especially when a single system dominates an entire county. Marcelle Crago’s experience was eye-opening because she was proactive enough to balk at the $9,000 price tag, which the hospital then tried to “discount” by 20% if she paid upfront—a tactic she rightly described as feeling predatory. She eventually found an outpatient center not affiliated with the monopoly that charged less than a third of that price, but many patients don’t have the time, health literacy, or geographic mobility to do that. In many cases, the attorney for a hospital like HCA Healthcare will argue that high charges cover “advanced technology and training,” but for a routine procedure like removing torn cartilage, those costs should not triple just because the hospital has no competitors. It puts the burden of price discovery on the individual, who is usually the least equipped person in the transaction to negotiate.
There is a common argument that mergers improve the quality of care through shared resources, yet research often suggests the opposite. What is happening to the actual patient experience inside these consolidated systems?
The theory that consolidation leads to better care is frequently debunked by the reality of staff cuts and physician turnover that often follows a major acquisition. In Asheville, the community has seen “immediate jeopardy” findings from state health inspectors three times since 2024, which indicates problems so severe they pose an imminent risk of death or serious injury. We see tragic outcomes, like the case of an 88-year-old woman who died after going an entire night without a required blood transfusion while recovering from surgery. When a system like Mission Hospital is charging 334% of Medicare rates but still failing basic safety checks, it suggests that the profits gained from the monopoly are not being reinvested back into the bedside staff or patient safety. Quality of care tends to decline when there is no competitive pressure to keep doctors happy or keep the facility at peak performance.
Several states, including Minnesota, California, and Oregon, have recently passed laws to curb healthcare monopolies. Do you believe state-level intervention is enough to reverse this multi-decade trend?
The state-level actions are a necessary first step, particularly California’s 90-day notice requirement for large mergers and Minnesota’s ban on anti-competitive healthcare deals, but they face a massive uphill battle against the momentum of the last twenty years. At the federal level, we’ve seen a lot of wavering; while the FTC has recently challenged five hospital mergers, they only intervened in about 1% of the 1,000+ mergers that occurred between 2002 and 2020. The challenge is that once a monopoly is formed—like the “prepackaged monopoly” that was handed to HCA Healthcare when it bought Mission Health—it is incredibly difficult to dismantle. States are trying to regain oversight that was lost, such as when North Carolina dropped profit limits on Mission in 2015, but until there is a consistent, aggressive federal policy that transcends political administrations, hospitals will continue to seek growth as a way to gain leverage over insurers.
What is your forecast for the future of healthcare pricing if the current pace of hospital consolidation continues?
If the current trajectory of “mega-mergers” remains unchecked, I forecast that we will see the total disappearance of the independent community hospital in most mid-sized American markets, leading to a standardized “monopoly price” that is decoupled from local economic realities. We will likely see more interstate systems like the Sanford-Marshfield link, where revenue reaches the $10 billion mark, giving these entities more political and economic power than the states they operate in. For the consumer, this means that the $27,000 family insurance premium we see today will likely become a baseline that continues to outpace inflation, eventually forcing a radical shift in how we fund healthcare or a massive increase in the number of people who simply cannot afford basic procedures like a knee replacement or hernia repair. Without a significant increase in the FTC’s intervention rate beyond that 1% mark, the “cautionary tale” of Asheville will become the standard experience for the majority of American patients.
